medRxiv PreprintsInternational2 October 2026
Lanreotide for Advanced Pheochromocytoma and Paraganglioma: Results of a Multicenter Phase II Trial
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
Background: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine neoplasms originating from chromaffin cells that express somatostatin receptors (SSTRs) and may therefore be susceptible to somatostatin analogue therapy. Despite this biological rationale, prospective evidence supporting the antiproliferative activity of somatostatin analogues in PPGL is limited. We conducted a multicenter phase 2 clinical trial to assess the efficacy and safety of lanreotide in patients with advanced or metastatic PPGL. [LAMPARA, NCT03946527] Methods: Patients with advanced or metastatic PPGL an
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- Exploring Ensemble Selection for Model Averaging in Model-informed Precision Dosing: A Tacrolimus Case Study Extended to Cefepime and InfliximabExploring Ensemble Selection for Model Averaging in Model-informed Precision Dosing: A Tacrolimus Case Study Extended to Cefepime and Infliximab2 October 2026
- Reliability and accuracy of medication-based performance measures for assessment of outpatient cardiology clinicians2 October 2026
- Rare Germline Variants and Genetic Susceptibility to Pleural Mesothelioma: Moving Beyond DNA Repair2 October 2026
- Interaction Between Exercise Intensity and Sedentary Behavior on VO2max Change in Patients with De Novo Parkinson Disease: The Study in Parkinson Disease of Exercise (SPARX) Phase 2 Randomized Clinical Trial2 October 2026
- Effects of a standardised Amaranthus tricolor-Spinacia oleracea extract on exercise performance, muscle strength, endurance and recovery in active adults: a randomised, double-blind, placebo-controlled trial2 October 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program — especially if you are pregnant, nursing, taking medication, or managing a health condition.